ZEMAIRA Drug Insight

“ZEMAIRA Drug Insight and Market Forecast – 2032” report provides comprehensive insights about ZEMAIRA for Alpha-1 Antitrypsin Deficiency (AATD) in the six major markets. A detailed picture of the ZEMAIRA for AATD in the 6MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom for the study period 2019 –2032 is provided in this report along with a detailed description of the ZEMAIRA for AATD. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the ZEMAIRA market forecast analysis for AATD in the 6MM, SWOT, analysts’ views, comprehensive overview of market competitors, and brief about other emerging therapies in AATD.

Drug Summary

ZEMAIRA, a highly-purified form of AAT (human), is indicated to raise the plasma level of A1-PI in patients with A1-PI deficiency and related emphysema. The drug is administered intravenously and helps the fast infusion in the body, giving early relief. It is currently approved in the US, Canada, Brazil, and New Zealand, where it is indicated for chronic augmentation and maintenance therapy in adults with AATD and clinical evidence of emphysema. CSL Behring markets ZEMAIRA as RESPREEZA in Europe. The recommended dosage for treating AATD patients is 60 mg/kg body weight, administered weekly.

In April 2019, CSL Behring announced that the US FDA approved 4 g and 5 g vial sizes for ZEMAIRA for treating AATD. This approval is significant for the alpha-1 community as ZEMAIRA was previously available in a 1 g vial. The 4 g and 5 g packaging reduces the number of vials necessary for reconstitution, thereby adding convenience by saving the patient’s time and reducing waste.

Scope of the Report

The report provides insights into:

• A comprehensive product overview including the ZEMAIRA description, mechanism of action, dosage and administration, research and development activities in AATD.
• Elaborated details on ZEMAIRA regulatory milestones and other development activities have been provided in this report.
• The report also highlights the ZEMAIRA research and development activities in AATD across the United States and Europe.
• The report also covers the patents information with expiry timeline around ZEMAIRA.
• The report contains forecasted sales of ZEMAIRA for AATD till 2032.
• Comprehensive coverage of the late-stage emerging therapies for AATD.
• The report also features the SWOT analysis with analyst views for ZEMAIRA in AATD.

Methodology

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

ZEMAIRA Analytical Perspective by DelveInsight

In-depth ZEMAIRA Market Assessment

This report provides a detailed market assessment of ZEMAIRA for AATD in the six major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom. This segment of the report provides forecasted sales data from 2023 to 2032.

ZEMAIRA Clinical Assessment

The report provides the clinical trials information of ZEMAIRA for AATD covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights

• In the coming years, the market scenario for AATD is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence ZEMAIRA dominance.
• Other emerging products for AATD are expected to give tough market competition to ZEMAIRA and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of ZEMAIRA in AATD.
• Our in-depth analysis of the forecasted sales data of ZEMAIRA from 2023 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the ZEMAIRA in AATD.

Key Questions

• What is the product type, route of administration and mechanism of action of ZEMAIRA?
• What is the clinical trial status of the study related to ZEMAIRA in AATD and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the ZEMAIRA development?
• What are the key designations that have been granted to ZEMAIRA for AATD?
• What is the forecasted market scenario of ZEMAIRA for AATD?
• What are the forecasted sales of ZEMAIRA in the six major countries, including the United States and Europe (Germany, France, Italy, Spain, and the United Kingdom)?
• What are the other emerging products available and how are these giving competition to ZEMAIRA for AATD?
• Which are the late-stage emerging therapies under development for the treatment of AATD?